The Week Ahead: Hom...
Health Care: Drugs
Cyclacel Pharmaceuticals Inc. (CYCC: NASDAQ)
$3.04 0.04 | 1.33%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 69.00K | 699.00K | 686.00K | 911.00K |
| Cost of Sales | 0.00 | 119.00K | 418.00K | 545.00K |
| Gross Operating Profit | 69.00K | 580.00K | 268.00K | 366.00K |
| Selling, General, and Administrative Expenses | 8.58M | 7.52M | 10.12M | 8.54M |
| Research & Development | 6.59M | 9.21M | 6.41M | 9.77M |
| Operating Income before D & A (EBITDA) | -15.10M | -16.15M | -16.27M | -17.94M |
| Depreciation & Amortization | 60.00K | 241.00K | 457.00K | 690.00K |
| Interest Income | 22.00K | 45.00K | 37.00K | 102.00K |
| Other Income - Net | -26.00K | 535.00K | -406.00K | -2.14M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -15.17M | -15.81M | -17.09M | -21.03M |
| Interest Expense | 0.00 | 0.00 | 43.00K | 177.00K |
| Pre-Tax Income | -15.17M | -15.81M | -17.14M | -21.21M |
| Income Taxes | -1.35M | -565.00K | -657.00K | -948.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -13.76M | -15.24M | -16.02M | -19.57M |
| Net Income From Discontinued Operations | 570.00K | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -13.19M | -15.24M | -16.02M | -19.57M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -13.19M | -15.24M | -16.02M | -19.57M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-13.76M | -15.24M | -16.02M | -19.20M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -14.48M | -15.97M | -19.70M | -19.57M |
| Basic EPS from Continuing Ops. | -1.75 | -2.24 | -3.64 | -6.16 |
| Basic EPS from Discontinued Ops. | 0.07 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.68 | -2.24 | -3.64 | -6.16 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.68 | -2.24 | -3.64 | -6.16 |
| Basic Normalized Net Income/Share | -1.75 | -2.24 | -3.64 | -6.04 |
| EPS fr Continuing Ops. | -1.75 | -2.24 | -3.64 | -6.16 |
| EPS fr Discontinued Ops | 0.07 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.68 | -2.24 | -3.64 | -6.16 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.68 | -2.24 | -3.64 | -6.16 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.75 | -2.24 | -3.64 | -6.04 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CYCC
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Uservlady 1
- Contributor13 Biotech Stocks Bought an...
- ProWilbur Ross - Invesco Priva...
- Contributor10 Cheap Biotech Stocks Tha...
- Userjeezlola
Latest CYCC Headlines from TheStreet
- Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering 05.16.13 | 09:05 am
- Cyclacel Pharmaceuticals Announces Proposed Public Offering Of Common Stock 05.15.13 | 04:05 pm
- Cyclacel Reports First Quarter 2013 Financial Results 05.13.13 | 04:05 pm
- Cyclacel Pharmaceuticals To Announce Release Of First Quarter 2013 Financial Results 05.10.13 | 07:05 am
- Cyclacel Reports Updated Phase 2 Survival Data Of Sapacitabine For MDS 04.30.13 | 07:04 am
- Cyclacel Pharmaceuticals To Present At The 12th Annual Needham Healthcare Conference 04.23.13 | 07:04 am
- Reminder: Cyclacel Pharmaceuticals' 6% Preferred Stock Goes Ex-Dividend Soon 04.16.13 | 01:04 pm
- Combination Potential Of Cyclacel's Sapacitabine And Seliciclib Reported At AACR 04.09.13 | 02:04 pm
- AACR Press Conference Highlights Combination Potential Of Two Cyclacel Drugs 04.08.13 | 07:04 am
- Cyclacel Announces Sale Of Four Cyclacel Romidepsin-Related Patents To Celgene And Dismissal Of All Claims In Their Patent Litigation 04.04.13 | 07:04 am
Press Releases for CYCC
Partner Headlines for CYCC
- Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th - Benzinga 12.04.12 | 09:12 am
- Upcoming AML Treatments - Which Company Will Fly? - Seeking Alpha 12.03.12 | 09:12 am
- 4 Cash Loaded Biotech Stocks With Little Debt - Seeking Alpha 08.30.12 | 09:08 am
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Cyclacel: An Intriguing Long Shot - Seeking Alpha 03.20.12 | 08:03 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.18.11 | 09:11 am
- Buy And Sell Ideas Based On Wednesday's Big News And Price Decliners - Seeking Alpha 09.29.11 | 08:09 am
- The Biotech Bump: Cyclacel Pharmaceuticals - Benzinga 07.28.11 | 01:07 pm
- Profit From These 3 Analysts' Stock Picks for Under $10 - Seeking Alpha 07.13.11 | 09:07 am
